ResApp Provides Updated Paediatric Clinical Study Results

View printer-friendly version New accuracy benchmarks achieved using an expanded 524 subject dataset (186 additional subjects since previously released results) Correctly detected lower respiratory tract disease in 97% of patients who were initial diagnosed as clear...

ResApp Completes Successful Pre-Submission Meeting with the US FDA

View printer-friendly version ResApp Health Limited (ASX: RAP), announced today a positive outcome from its recent Pre-Submission Meeting with the United States Food and Drug Administration (FDA) regarding ResApp’s diagnostic mobile software application, ResAppDx....

ResApp Achieves Breakthrough Performance in Paediatric Clinical Study

View printer-friendly version Correctly detected lower respiratory tract disease in 80% of patients who were initially diagnosed as clear by experienced clinicians using stethoscopes – but were finally diagnosed as having a lower respiratory tract disease after...